LEGN stock holds after Legend Biotech reports 2025 revenue growth

Legend Biotech (US52490G1022) enters the latest trading window with a 2025 revenue base of $750.6 million, up 68.7% from $445.4 million in 2024, while continuing operations still showed a net loss of $64.0 million for the year. The company said on its investor relations site that the commercial profile was led by CARVYKTI and that cash and cash equivalents stood at $1.7 billion at 31 December 2025, giving the balance sheet a larger cushion than a year earlier.

Revenue up 68.7%

The 2025 top line gives the clearest recent number: Legend Biotech generated $750.6 million in revenue, compared with $445.4 million in 2024, a rise of $305.2 million. That growth rate of 68.7% matters because it shows the company is still scaling a commercial product rather than relying only on pipeline expectations.

The same 2025 reporting period also showed $64.0 million in net loss from continuing operations, which is far smaller than the revenue line but still leaves profitability as the main gap between growth and full earnings leverage. Cash and cash equivalents of $1.7 billion at 31 December 2025 help explain why investors can focus on execution rather than immediate financing risk.

CARVYKTI drives sales

Legend Biotech has repeatedly tied its commercial momentum to CARVYKTI, the BCMA-directed CAR-T therapy it markets with Johnson & Johnson. In the company’s 2025 reporting context, that product remains the key operating engine behind the jump in revenue, and the scale of $750.6 million suggests the launch curve is still developing.

For investors, the combination of $750.6 million in annual revenue, 68.7% year-over-year growth, and a $64.0 million continuing-operations loss frames the stock as a growth story with visible commercialization, but not yet a clean earnings story. The $1.7 billion cash balance at year-end 2025 also means the company could keep funding that rollout without immediate balance-sheet pressure.

Market value missing here

Because a dated live quote was not available in the current evidence set, the focus stays on the company’s latest reported numbers rather than a specific session move. The most decision-relevant market context in the available records is the 31 December 2025 cash balance of $1.7 billion and the 2025 revenue base of $750.6 million.

That makes the next read-through straightforward: revenue growth is still outrunning cost absorption, and the market will continue to weigh commercial traction against the continued loss line.

Product momentum

CARVYKTI remains the product that defines the Legend Biotech equity story. The 2025 figures show why: a single marketed therapy is now tied to a revenue run rate that moved from $445.4 million in 2024 to $750.6 million in 2025, which is the kind of step-up investors watch for when a biotech tries to scale into a broader commercial company.

That also helps explain why operating updates on uptake, reimbursement, and manufacturing execution matter more than abstract pipeline language. In Legend Biotech’s case, the product line is already large enough to move the annual income statement.

Trading level watch

Without a verified same-day price in the available evidence, the stock cannot be anchored to a session quote here. The article therefore stays with the dated fundamental markers that are already visible: 2025 revenue of $750.6 million, 2024 revenue of $445.4 million, and a $64.0 million continuing-operations loss in 2025.

Those figures are enough to frame the equity: Legend Biotech stock is trading around a business that is growing quickly, holding substantial cash, and still working through the final stretch from scale-up to profit.